Targocid (teicoplanin) is not licensed by the US FDA, but generic teicoplanin now sits alongside the Sanofi brand on UK, EU, GCC and African hospital formularies, where its once-daily dosing makes it a mainstay of outpatient parenteral antibiotic therapy.
Targocid (teicoplanin), originated by Sanofi, is a glycopeptide antibiotic for serious Gram-positive infections, including MRSA, dosed once daily after a loading regimen. M Care Exports is a merchant exporter: we source Targocid and licensed generic teicoplanin through Indian WHO-GMP manufacturing channels and dispatch against a buyer's own specification, never from our own manufacturing.
Teicoplanin exporter and bulk supplier from India.
For hospital pharmacy, wholesaler and MoH tender orders, M Care quotes teicoplanin 200mg and 400mg vials against buyer specification: originator Targocid or a licensed generic line, IV or IM presentation, and the destination market's own import documentation. Teicoplanin is a room-temperature powder for injection with no cold-chain requirement, which keeps freight simpler than for many glycopeptide and biologic lines on the same tender.
Source
WHO-GMP-certified Indian manufacturing line, named on every quote.
Minimum order
No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.
Pricing
On request. Indicative FOB or CIF quote, formal proforma on confirmation.
Incoterms
EXW, FOB, CIF, CIP or DAP.
Payment
Letter of credit (sight or usance) and telegraphic transfer.
Documentation
WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.
Shelf-life
Minimum remaining shelf-life agreed per order and confirmed on the proforma.
Response
Availability and CoPP status within two working days; pre-alert documents before dispatch.
Glycopeptide antibacterial, structurally related to vancomycin with an added lipophilic side chain, sourced and documented for export.
Teicoplanin is a glycopeptide antibacterial, structurally related to vancomycin but carrying an additional lipophilic side chain that gives it a longer elimination half-life and, per the harmonised EU SmPC, a lower reported rate of nephrotoxicity than high-dose vancomycin. It is bactericidal against Gram-positive organisms, including meticillin-resistant Staphylococcus aureus (MRSA), by inhibiting bacterial cell-wall synthesis. The EU-harmonised indication set, agreed by the European Commission's 2013 Targocid Article 30 referral decision, covers serious Gram-positive infections in adults and children: skin and soft-tissue infections, bone and joint infections, pneumonia, urinary tract infections, infective endocarditis, and bacteraemia associated with any of these. It also covers continuous ambulatory peritoneal dialysis (CAPD)-related peritonitis, and, given orally rather than intravenously, Clostridioides difficile infection-associated diarrhoea and colitis. Teicoplanin is not FDA-approved and is not marketed in the United States; it is used across the UK, EU, GCC and African markets M Care serves. It is supplied as a powder for solution for injection or infusion in 200mg and 400mg vials, reconstituted with water for injection and given by IV bolus, 30-minute IV infusion or IM injection; the same reconstituted solution is administered orally for C. difficile indications. The powder is stable for up to 3 years at room temperature; no cold-chain handling is required.
Active ingredient
teicoplanin (a mixture of five closely related glycopeptide components, TA2-1 to TA2-5). Glycopeptide antibacterial, structurally related to vancomycin with an added lipophilic side chain.
Forms and strengths
200 mg vial powder for solution for injection/infusion; 400 mg vial powder for solution for injection/infusion.
Indications
Teicoplanin is a glycopeptide antibacterial for serious Gram-positive infections, including MRSA, dosed once daily after a loading regimen. Supplied from Indian WHO-GMP facilities as both originator Targocid and licensed generic lines, to regulated and semi-regulated markets outside the United States.
Administration
intravenous, intramuscular, oral. Powder for solution for injection/infusion, reconstituted; the same reconstituted solution is given orally for Clostridioides difficile indications.
Documentation
Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.
Hospital pharmacies, licensed importers and tender desks across our export markets.
India is our origin. We do not sell into the Indian market.
Buyers for teicoplanin are hospital microbiology and infectious-disease pharmacists managing MRSA and other resistant Gram-positive infections, NHS trust and MoH tender desks running anti-infective procurement lists, OPAT (outpatient parenteral antibiotic therapy) and home-IV service providers who value teicoplanin's once-daily dosing over vancomycin's continuous-infusion regimens, CAPD renal units, and licensed importers and wholesalers stocking hospital anti-infective ranges across our GCC and African markets.
GCC registration routes
Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.
UK unlicensed routes
Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.
Tender desks
Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.
Dossier support
CTD documentation from the sourcing manufacturer, compiled for your regulator's format.
What the dispensing pharmacist checks on teicoplanin.
Teicoplanin dosing is weight-based and indication-dependent: 6mg/kg every 12 hours for three doses then 6mg/kg once daily for skin, soft-tissue, urinary and respiratory infections, rising to 12mg/kg every 12 hours for three to five doses then 12mg/kg once daily for bone/joint infection and endocarditis, where trough monitoring matters most. After day 4, halve the maintenance dose in moderate renal impairment (CrCl 30-80 mL/min) and reduce to one-third in severe impairment (CrCl below 30 mL/min). Reconstitute each vial with water for injection and rotate the vial gently between the palms; shaking causes the solution to foam and makes accurate dosing difficult. A reconstituted vial holds for 24 hours refrigerated at 2-8C. Because teicoplanin shares a glycopeptide backbone with vancomycin, hypersensitivity cross-reactivity is possible; pharmacies managing a documented vancomycin allergy should still treat a first teicoplanin dose as a monitored exposure rather than an automatic substitute. Serum trough concentration monitoring is standard practice for regimens beyond a few days, alongside routine renal function checks.
The documentation pack a regulator actually asks for.
Teicoplanin ships as a room-temperature powder for injection, so M Care's documentation chain for this molecule runs on the standard non-biologic export file: batch-specific certificate of analysis, WHO-GMP manufacturing site documentation from the sourcing partner, and CDSCO export paperwork from the Mumbai desk, with CTD/eCTD dossier support for destination markets, such as MHRA, SFDA, MOHAP, NAFDAC, PPB or SAHPRA, that require local registration or tender-listing documentation before import. Teicoplanin is tracked within WHO's AWaRe antimicrobial monitoring framework, reserved for infections where narrower-spectrum options have failed or are unsuitable; it has never been carried on the WHO Essential Medicines List. Buyers running antimicrobial-stewardship programmes should factor that status into formulary justification. On brand versus generic: Targocid remains Sanofi's originator product, and the EU harmonised indication set (including the oral C. difficile use) now applies across licensed generic teicoplanin lines as well, marketed in the UK by manufacturers including Martindale Pharma (Teicoplanin Altan) and other MHRA-licensed suppliers. M Care sources either the Sanofi brand through licensed Indian distribution channels or a generic teicoplanin line from a WHO-GMP partner site, quoted against the buyer's own tender or formulary specification. We do not manufacture teicoplanin ourselves and hold no WHO-GMP or WHO-PQ certification in our own name; every batch we export carries its manufacturing partner's own certification.
If your question is the route rather than the molecule, start with the licensed route for importing medicines from India and come back here for the product specifics.
CoA and MoA, per batch
Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.
CoPP, WHO-GMP, MFG licence
Certificate of pharmaceutical product and site GMP certification issued via CDSCO channels, naming the actual manufacturing site.
CTD Module 3
Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.
Pack insert, labels, artwork
Destination-language patient information and labelling to the local regulator's standard, locked before shipment.
Pharmacovigilance
A named PV contact arranged in the destination market where the registration requires one.
Adjacent lines procurement desks order alongside teicoplanin.
Molecule · strength · volume · destination. One working day to a quote.
- Send us the specifics. Form and strength, pack preference, destination market and indicative volume for teicoplanin.
- We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
- Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
- Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
- After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Teicoplanin supply, the specific questions.
Is teicoplanin approved by the US FDA?
No. Teicoplanin has never received FDA marketing approval and is not sold in the United States. It has held marketing authorisation across EU member states since the late 1980s and is used throughout the UK, GCC and African markets M Care serves. Buyers sourcing for a US-facing formulary should note this before specifying teicoplanin on a tender.
Is there a generic version of Targocid?
Yes. Licensed generic teicoplanin is marketed in the UK and EU alongside Sanofi's originator Targocid, including lines from manufacturers such as Martindale Pharma. M Care can source either the brand or a generic teicoplanin line from a WHO-GMP partner site, depending on what your tender or formulary specification requires.
Does teicoplanin need cold-chain shipping?
No. Teicoplanin is a powder for solution for injection or infusion, stable for up to three years at room temperature. It ships and stores under standard ambient, GDP-compliant conditions rather than the validated cold-chain lanes we use for biologics.
Why do hospitals choose teicoplanin over vancomycin for OPAT?
Teicoplanin's long elimination half-life allows once-daily IV or IM dosing after an initial loading regimen, unlike vancomycin's usual twice-daily or continuous-infusion schedule. That once-daily profile suits outpatient parenteral antibiotic therapy and home-IV nursing rounds, which is why many OPAT services list it as a first-line glycopeptide.
What strengths of teicoplanin does M Care supply?
200mg and 400mg vials of powder for solution for injection or infusion, matching the originator Targocid presentation and the equivalent licensed generic lines. Tell us your dosing protocol, indication mix and volumes and we quote the strength split accordingly.
What documentation does M Care provide with a teicoplanin shipment?
Batch-specific certificate of analysis, WHO-GMP manufacturing site documentation from the sourcing partner, and CDSCO export paperwork from India, with CTD/eCTD-format dossier support where the destination regulator requires local registration or tender-listing evidence before import.
Who stands behind this page, and where its statements come from.
Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-09-11.
This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.
Send the specifics. You'll have a price inside one working day.
Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.